Participants who meet the following eligibility criteria will be selected from the registry:

Participants of 18 years of age or older at the time of infusion

Participants with a diagnosis of relapsed or refractory marginal zone lymphoma (R/R MZL)

Participants have received at least two prior lines of systemic therapy

Participants have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel:

* used for the treatment of R/R MZL,

* within the FDA-approved indication and dosage per the United States prescribing information and

* product specifications approved for commercial release in the USA.

Participants have consented to share their data with the registry and the Sponsor.

Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma